晚期上皮性卵巢癌：我们是否真的改善了70岁及以上患者的护理？一项基于20年登记的研究

IF 3.2 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2025-05-10 DOI:10.1016/j.clon.2025.103860

J. Barben , A. Mamguem Kamga , V. Quipourt , S. Marilier , J. Niogret , L. Bengrine-Lefevre , T.S. Dabakuyo-Yonli

{"title":"晚期上皮性卵巢癌：我们是否真的改善了70岁及以上患者的护理？一项基于20年登记的研究","authors":"J. Barben , A. Mamguem Kamga , V. Quipourt , S. Marilier , J. Niogret , L. Bengrine-Lefevre , T.S. Dabakuyo-Yonli","doi":"10.1016/j.clon.2025.103860","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Advanced epithelial ovarian cancer (aEOC, International Federation of Gynecology and Obstetrics(FIGO) stages IIIC-IV) is the most frequently diagnosed and lethal form of ovarian cancer. The aim of this study was to evaluate net survival (NS) over time and the differences between younger (<70 years) and older (≥70 years) patients (OPs).</div></div><div><h3>Materials and Methods</h3><div>All patients with aEOC diagnosed in the French department of Côte d'Or between 01 January 1998 and 31 December 2018 were included. Two-year and 5-year NS were calculated for the two age groups over three periods: 1998 to 2004 (T1), 2005 to 2011 (T2), and 2012 to 2018 (T3).</div></div><div><h3>Results</h3><div>A total of 392 patients were included, of whom 154 (39.3%) were aged ≥70 years. Surgery-based treatment was used less frequently in OPs (58.15% vs 83.41%, <em>P</em> < 0.0001) and decreased over time, notably in OPs (74.2% at T1 vs 34.8% at T3, <em>P</em> < 0.001). There was a clear increase in chemotherapy alone at T3 vs T1 in OPs (odds ratio = 8.14, 95% confidence interval [CI]: [2.49-26.58], <em>P</em> < 0.001). The 5-year NS was lower in OPs (23.3%, 95% CI: [17.1-31.8] vs 44.6%, 95% CI: [38.7%-51.6%], <em>P</em> < 0.001) over the 20-year period. The only significant difference in NS between patients aged ≥70 years and <70 years was observed during T3, 17.9% (95% CI: [10.9-29.5]) vs 42.9% (95% CI: [33.8-54.4], <em>P</em> < 0.001) for 5-year NS.</div></div><div><h3>Conclusion</h3><div>NS for aEOC was lower in women aged ≥70 years, especially from 2012 to 2018. Nonoptimal treatment was also more frequent in the older age group.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"43 ","pages":"Article 103860"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advanced Epithelial Ovarian Cancer: Have We Really Improved Care for Patients Aged 70 Years and Older? A 20-year Registry-based Study\",\"authors\":\"J. Barben , A. Mamguem Kamga , V. Quipourt , S. Marilier , J. Niogret , L. Bengrine-Lefevre , T.S. Dabakuyo-Yonli\",\"doi\":\"10.1016/j.clon.2025.103860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><div>Advanced epithelial ovarian cancer (aEOC, International Federation of Gynecology and Obstetrics(FIGO) stages IIIC-IV) is the most frequently diagnosed and lethal form of ovarian cancer. The aim of this study was to evaluate net survival (NS) over time and the differences between younger (<70 years) and older (≥70 years) patients (OPs).</div></div><div><h3>Materials and Methods</h3><div>All patients with aEOC diagnosed in the French department of Côte d'Or between 01 January 1998 and 31 December 2018 were included. Two-year and 5-year NS were calculated for the two age groups over three periods: 1998 to 2004 (T1), 2005 to 2011 (T2), and 2012 to 2018 (T3).</div></div><div><h3>Results</h3><div>A total of 392 patients were included, of whom 154 (39.3%) were aged ≥70 years. Surgery-based treatment was used less frequently in OPs (58.15% vs 83.41%, <em>P</em> < 0.0001) and decreased over time, notably in OPs (74.2% at T1 vs 34.8% at T3, <em>P</em> < 0.001). There was a clear increase in chemotherapy alone at T3 vs T1 in OPs (odds ratio = 8.14, 95% confidence interval [CI]: [2.49-26.58], <em>P</em> < 0.001). The 5-year NS was lower in OPs (23.3%, 95% CI: [17.1-31.8] vs 44.6%, 95% CI: [38.7%-51.6%], <em>P</em> < 0.001) over the 20-year period. The only significant difference in NS between patients aged ≥70 years and <70 years was observed during T3, 17.9% (95% CI: [10.9-29.5]) vs 42.9% (95% CI: [33.8-54.4], <em>P</em> < 0.001) for 5-year NS.</div></div><div><h3>Conclusion</h3><div>NS for aEOC was lower in women aged ≥70 years, especially from 2012 to 2018. Nonoptimal treatment was also more frequent in the older age group.</div></div>\",\"PeriodicalId\":10403,\"journal\":{\"name\":\"Clinical oncology\",\"volume\":\"43 \",\"pages\":\"Article 103860\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0936655525001153\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0936655525001153","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的晚期上皮性卵巢癌（aEOC, International Federation of Gynecology and Obstetrics， FIGO） IIIC-IV期)是卵巢癌中最常见和最致命的一种。本研究的目的是评估净生存（NS）随时间的变化以及年轻（≥70岁）和老年（≥70岁）患者（OPs）之间的差异。材料和方法纳入1998年1月1日至2018年12月31日期间在法国Côte d'Or科诊断的所有aEOC患者。计算两个年龄组1998 - 2004年（T1）、2005 - 2011年（T2）和2012 - 2018年（T3）三个时期的2年和5年NS。结果共纳入392例患者，其中年龄≥70岁154例（39.3%）。手术治疗在OPs中较少使用(58.15% vs 83.41%, P <；0.0001)，并随着时间的推移而下降，尤其是OPs (T1时74.2%，T3时34.8%,P <；0.001)。与T1相比，T3时单独化疗明显增加(优势比= 8.14,95%可信区间[CI]: [2.49-26.58], P <；0.001)。5年NS低于OPs (23.3%, 95% CI: [17.1-31.8] vs . 44.6%, 95% CI: [38.7%-51.6%], P <；0.001)。≥70岁和≥70岁患者的NS唯一显著差异是在T3期间，分别为17.9% （95% CI:[10.9-29.5]）和42.9% (95% CI: [33.8-54.4]), P <；0.001)。结论≥70岁女性aEOC的ns较低，尤其是2012 - 2018年。非最佳治疗在老年组中也更为常见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advanced Epithelial Ovarian Cancer: Have We Really Improved Care for Patients Aged 70 Years and Older? A 20-year Registry-based Study

Aims

Advanced epithelial ovarian cancer (aEOC, International Federation of Gynecology and Obstetrics(FIGO) stages IIIC-IV) is the most frequently diagnosed and lethal form of ovarian cancer. The aim of this study was to evaluate net survival (NS) over time and the differences between younger (<70 years) and older (≥70 years) patients (OPs).

Materials and Methods

All patients with aEOC diagnosed in the French department of Côte d'Or between 01 January 1998 and 31 December 2018 were included. Two-year and 5-year NS were calculated for the two age groups over three periods: 1998 to 2004 (T1), 2005 to 2011 (T2), and 2012 to 2018 (T3).

Results

A total of 392 patients were included, of whom 154 (39.3%) were aged ≥70 years. Surgery-based treatment was used less frequently in OPs (58.15% vs 83.41%, P < 0.0001) and decreased over time, notably in OPs (74.2% at T1 vs 34.8% at T3, P < 0.001). There was a clear increase in chemotherapy alone at T3 vs T1 in OPs (odds ratio = 8.14, 95% confidence interval [CI]: [2.49-26.58], P < 0.001). The 5-year NS was lower in OPs (23.3%, 95% CI: [17.1-31.8] vs 44.6%, 95% CI: [38.7%-51.6%], P < 0.001) over the 20-year period. The only significant difference in NS between patients aged ≥70 years and <70 years was observed during T3, 17.9% (95% CI: [10.9-29.5]) vs 42.9% (95% CI: [33.8-54.4], P < 0.001) for 5-year NS.

Conclusion

NS for aEOC was lower in women aged ≥70 years, especially from 2012 to 2018. Nonoptimal treatment was also more frequent in the older age group.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.